Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models

Gemcitabine (GEM) is first-line therapy for pancreatic cancer but has limited efficacy in most cases. Nanoparticle-albumin bound (nab)-paclitaxel is becoming first-line therapy for pancreatic cancer, but also has limited efficacy for pancreatic cancer. Our goal was to improve the treatment outcome i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Cycle
Glavni autori: Kawaguchi, Kei, Miyake, Kentaro, Zhao, Ming, Kiyuna, Tasuku, Igarashi, Kentaro, Miyake, Masuyo, Higuchi, Takashi, Oshiro, Hiromichi, Bouvet, Michael, Unno, Michiaki, Hoffman, Robert M.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224272/
https://ncbi.nlm.nih.gov/pubmed/29963961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1480223
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items